Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year of 2024. For the year, the company expects total revenue to be in the range of $140.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9602 USD | -1.31% | -0.92% | +11.01% |
May. 08 | Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M | MT |
May. 08 | Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.01% | 120M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024